RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
  Cataract
  Cornea
  Retina
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Ophthalmology Channel

subscribe to Ophthalmology newsletter
Latest Research : Ophthalmology

   EMAIL   |   PRINT
Older Children Can be Effectively Treated for Lazy Eye

Apr 13, 2005 - 8:05:00 PM
The study also revealed that among children age 13 through 17 years who had not been previously treated for amblyopia, 47 percent of those who were treated with glasses, patching and near activities improved two lines or more compared with only 20 percent of those treated with glasses alone. Despite the benefits of the treatment, most children, including those who responded to treatment, were left with some visual impairment.

 
[RxPG] Surprising results from a nationwide clinical trial show that many children age seven through 17 with amblyopia (lazy eye) may benefit from treatments that are more commonly used on younger children.

Treatment improved the vision of many of the 507 older children with amblyopia studied at 49 eye centers. Previously, eye care professionals often thought that treating amblyopia in older children would be of little benefit. The study results, funded by the National Eye Institute (NEI), part of the National Institutes of Health (NIH), appear in the April issue of Archives of Ophthalmology.

"Doctors can now feel confident that traditional treatments for amblyopia will work for many older children," said Paul A. Sieving, M.D., Ph.D., director of the NEI. "This is important because it is estimated that as many as three percent of children in the United States have some degree of vision impairment due to amblyopia. Many of these children do not receive treatment while they are young," he said.

Amblyopia is a leading cause of vision impairment in children and usually begins in infancy or childhood. It is a condition resulting in poor vision in an otherwise healthy eye due to unequal or abnormal visual input while the brain is developing in infancy and childhood. The most common causes of amblyopia are crossed or wandering eye (strabismus) or significant differences between the eyes in refractive error, such as, astigmatism, farsightedness, or nearsightedness.

Children in the study were divided randomly into two groups. One group was fitted with new prescription glasses only. The other group was fitted with glasses as well as an eye patch, or the eye patch along with special eye drops, to limit use of the unaffected eye. These children were also asked to perform near vision activities. The patching, near activities, and eye drops force a child to use the eye with amblyopia. Patching was prescribed for periods of two to six hours daily, while the eye drops were administered daily for the children seven though twelve years of age.

The study investigators defined successful vision improvement as the ability to read (with the eye with amblyopia) at least two more lines on a standard eye chart. The study investigators found that 53 percent of children age seven through twelve years who received both glasses and treatment with patches and near activity met this standard, while only 25 percent of those children in this age group who received glasses alone met the standard. For children age 13 through 17 years who were treated with both glasses and patches (these children did not get drops), 25 percent met the standard while 23 percent of children of these ages who received only glasses met the standard.

The study also revealed that among children age 13 through 17 years who had not been previously treated for amblyopia, 47 percent of those who were treated with glasses, patching and near activities improved two lines or more compared with only 20 percent of those treated with glasses alone. Despite the benefits of the treatment, most children, including those who responded to treatment, were left with some visual impairment. They did not obtain
"20/20" vision.

"This study shows how important it is to screen children of all ages for amblyopia." said study co-chairman Richard W. Hertle, M.D., Children's Hospital of Pittsburgh.

Commented co-chairman Mitchell M. Scheiman, O.D., Pennsylvania College of Optometry, "This study shows that age alone should not be used as a factor to decide whether or not to treat a child for amblyopia. The opportunity to treat amblyopia does not end with the pre-school years."

It is not known, say the authors of the current study, whether vision improvement will be sustained in these children once treatment is discontinued. The NEI is supporting a one-year, follow-up study to determine the percentage of amblyopia that recurs among the children who responded well to treatment, as well as many other clinical studies of amblyopia at eye centers nationwide.

Dr. Sieving also commented that the current study results are "a wonderful example of the adaptability of the human visual system and brain. The NIH is exploring ways to take advantage of this adaptability in order to better understand and treat vision problems and other neurological conditions."



Publication: Mayo Clinic
On the web: www.mayo.edu 

Advertise in this space for $10 per month. Contact us today.


Related Ophthalmology News
Simple blood or urine test to identify blinding disease
Breakthrough camera to improve detection of blinding eye disease and diabetes
Mayo Clinic researchers stop neuromyelitis optica attacks with new therapy
Patent issued for technology that improves eyesight dramatically
Mass. Eye and Ear, Joslin Diabetes announce collaboration in eye care
UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
Wayne State University researcher examines protein's role in diabetic retinopathy
Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
KalVista and JDRF form research partnership for novel treatment of diabetic eye disease
AMD-like lesions delayed in mice fed lower glycemic index diet

Subscribe to Ophthalmology Newsletter

Enter your email address:


 Additional information about the news article
The study described in this release was conducted by the NEI-funded Pediatric Eye Disease Investigator Group. The Group focuses on studies of childhood eye disorders that can be implemented by both university-based and community-based practitioners as part of their routine practice. The study was coordinated by the Jaeb Center for Health Research in Tampa, Florida. A list of study centers is attached.
----------------------------------
The National Eye Institute is part of the National Institutes of Health (NIH) and is the Federal government's lead agency for vision research that leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness. The NIH is an agency of the U.S. Department of Health and Human Services.
----------------------------------
Background
----------------------------------
Amblyopia is a condition that occurs when a child's visual system does not develop properly, resulting in abnormal sight in one or both eyes. The condition is sometimes called "lazy eye." The condition affects as many as three percent of children in the United States. It is the most common cause of monocular visual impairment in both children and young and middle-aged adults.

The disorder is caused by any condition that sends the brain abnormal or unequal visual input during infancy or childhood. These conditions can include an imbalance in the positioning of the eyes, such as strabismus, in which the eyes are crossed inward (esotropia) or turned outward (exotropia). Amblyopia also can result from a major difference in refractive error between the two eyes, such as nearsightedness, farsightedness, or astigmatism. Less common causes of amblyopia are cornea and lens diseases and injury to the eye of a young child. The results reported in this study do not include amblyopia from these less common causes.

It has been commonly thought that the best time to try to correct amblyopia was during infancy or early childhood before the eyes and the entire visual system, including the brain, have fully matured. Although most eye care professionals agreed that amblyopia could be treated effectively in young children, many have thought that treatment beyond a certain age is ineffective. Some clinicians thought that a treatment response was unlikely after the age of six or seven years, while others considered age nine or ten years to be the upper age limit for successful treatment.

There had been limited data available to eye researchers on treatment of children older than seven. However, some clinicians reported that treatment did benefit older children. To prepare for a possible randomized clinical trial on treating amblyopia in older children, the National Eye Institute (NEI) funded a pilot study that was completed in 2003. The pilot study showed that after treatment, 27 percent of 66 children with amblyopia, ages ten through 17 years, improved their vision in the affected eye. They gained the ability to read two or more lines of a standard eye chart. The results justified the NEI-funded, Randomized Trial of Treatment of Amblyopia in Children 7 to <18 years old
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)